https://www.tipranks.com/news/the-fly/syndaxs-revumenib-meets-primary-results-in-aml-trial Cencora (COR) announced that it has entered into a definitive agreement to ...

Cencora CEO Robert Mauch said the acquisition will allow his firm to expand its management services operations. Cencora Inc. entered into a definitive agreement Wednesday to acquire Retina ...

Hello, everyone, and thank you for your patience. Today is Cencora's Q4 full-year 2024 earnings call, we'll begin shortly. (Operator Instructions) Hello, everyone, and welcome to today's Cenciora ...

Cencora's Q4 sales rose 14.7% to $79.1 billion, exceeding $77.65 billion consensus; adjusted EPS increased 16.8% to $3.34. The Retina Consultants of America deal will add nearly 300 retina ...

Leading medical distributors McKesson (NYSE:MCK) and Cencora (NYSE:COR) will have to pay $266M in damages to Baltimore after a jury found that the companies were liable for causing the opioid ...

Nov 6 (Reuters) - Cencora (COR.N), opens new tab will buy Retina Consultants of America from private-equity firm Webster Equity Partners for $4.6 billion, the drug distributor said on Wednesday ...

Hello, everyone, and welcome to today's Cencora Q4 Full Year 2024 Earnings Call. My name is Drew, and I'll be the operator today. During today's call, there will be a Q&A session. [Operator ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 6.7% over the past month. The stock hit a new 52-week high of $251.56 in the previous session.

Cencora has a 52 week low of $184.00 and a 52 week high of $247.66. The firm’s 50-day simple moving average is $231.39 and its two-hundred day simple moving average is $230.60. 10 Stocks to Sell ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- Cencora, Inc. (NYSE: COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America (“RCA”), a leading ...

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles Rhyee has given his Buy rating due to a combination of ...